ImmuPharma, Avion sign licensing agreement for lupus drug Lupuzor in US

Avion and ImmuPharma will co-develop Lupuzor, including a new Phase III trial and Avion will commercialize the drug exclusively in the United States, ImmuPharma said.

New Delhi: British pharmaceutical firm ImmuPharma said on Thursday it had signed a licensing and development agreement for Lupuzor, a first-in-class treatment for auto-immune disease Lupus, with U.S. company Avion Pharmaceuticals.

Avion and ImmuPharma will co-develop Lupuzor, including a new Phase III trial and Avion will commercialize the drug exclusively in the United States, ImmuPharma said.

Read Also: GSK collaborates with Lyell Immunopharma on cancer cell therapies

The British company said it would receive milestone payments of up to $70 million, comprising $5 million upon regulatory approval and up to $65 million based on sales targets.

Read Also: Jacobus Pharma wins USFDA approval for Ruzurgi to treat a rare autoimmune disorder